Full-Time

Senior Principal Research Scientist – Computational Drug Discovery Optimization Team Lead

AbbVie

AbbVie

10,001+ employees

Global biopharmaceutical company developing medicines

Compensation Overview

$160.5k - $305k/yr

Waukegan, IL, USA

In Person

Category
Lab & Research (1)
Required Skills
Data Science
Machine Learning
Medicinal Chemistry
Requirements
  • Bachelor’s Degree or equivalent education in Science related field with extensive (typically > 18 years) of related work; Master’s Degree or equivalent education with extensive (typically > 16 years) of related work; PhD in Science or related field with typically 10+ years of related work experience
  • Highly organized and self-directed, experience leading multiple complex simultaneous research programs or initiatives
  • Extensive knowledge and experience in applying data science approaches for medicinal chemistry optimization
  • Extensive knowledge and experience in modern computational approaches for medicinal chemistry
  • Excellent written and verbal communication, as well as critical evaluation and data-driven decision making, particularly including an ability to explain complex ideas to non-specialists
  • Strong analytical and problem-solving skills with demonstrated ability to think critically and creatively, and provide solutions both individually and collaboratively with internal experts
  • Proven team leadership and management abilities, including experience mentoring, guiding, supervising, and developing scientific personnel with various backgrounds and training levels
  • Highly collaborative, team-oriented, and considerate of the needs of others
  • Strong interpersonal skills and ability to collaborate with diverse groups within the organization and external partners
  • Ability to create an inclusive environment where diverse ideas, viewpoints and backgrounds are valued; willingness and ability to lead inclusively and demonstrate a commitment to listen and consider all points of view
  • Preferred: has served as Project Lead for a campaign resulting in candidate nomination
  • Preferred: track record of driving design of early to late-stage discovery programs with inventive contributions to advanced programs
Responsibilities
  • Consult with project team and GMEC leadership to establish quantitative targets for driving optimization, and assigning an Optimization team member to the project team that can execute these goals for accelerated identification of low dose drug candidates
  • Guide Optimization team members in benchmarking experiments to evaluate models’ performance and domain of applicability
  • Clearly communicate to project teams the rationale behind the selection of specific models and why they are best suited for the task at hand
  • Lead the development of a cohesive collection of internal models and workflows, to comprehensively address AbbVie’s small molecule portfolio needs ( suitable models to predict small molecule binding affinities for protein targets, and to predict pharmacological properties (PK parameters, etc.))
  • Partner closely with the GMEC leadership team to identify and address gaps where computational predictions are needed
  • Advance scientific expertise within the Optimization team and collaborates with cross-disciplinary teams from CDD and Information Research to advance programs and ensure computational capabilities are best implemented across programs
  • Proactively demonstrate leadership by providing expert advice and shared knowledge with direct reports, peers, and senior management
  • Identify and integrate emerging scientific trends from internal and external sources into functional objectives
  • Present program updates and research strategies to functional and non-functional leaders as well as potential and existing partners
  • Maintain awareness of emerging literature and science in the field and author scientific disclosures/publications
  • Maintain scientific presence outside AbbVie with appropriate publications and conference abstract submission highlighting innovative learnings in computational medicinal chemistry
Desired Qualifications
  • None

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Your Connections

People at AbbVie who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • The Durham campus investment adds manufacturing capacity and 734 new jobs.
  • AQUIPTA's EU acute-migraine approval extends lifecycle value in headache care.
  • Oncology momentum and CLL data support a growing non-immunology revenue base.

What critics are saying

  • High leverage and negative equity constrain flexibility if growth slows.
  • Patent-cliff pressure after 2028 leaves Skyrizi and Rinvoq carrying too much risk.
  • Aesthetic and acquired-asset integration execution can disappoint and dilute returns.

What makes AbbVie unique

  • AbbVie combines blockbuster immunology with consumer aesthetics, diversifying revenue streams.
  • Skyrizi and Rinvoq have replaced Humira with rapid post-exclusivity growth.
  • A partnered-pipeline model expands oncology and neuroscience without fully funding early discovery.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
WirtschaftsWoche
Jun 19th, 2026
AbbVie reportedly set to acquire Apogee Therapeutics after $1.3B Blackstone funding

AbbVie is reportedly nearing an acquisition of Apogee Therapeutics, a biotechnology company developing therapies for inflammatory and immune diseases. Founded in 2022, Apogee recently secured financing of up to $1.3 billion from Blackstone Life Sciences last month to fund late-stage development and potential commercialisation of an eczema medication. No further details about the potential deal's terms or valuation have been disclosed.

National Institute for Labor Relations Research
Jun 11th, 2026
AbbVie adds new location in Right to Work North Carolina.

AbbVie adds new location in Right to Work North Carolina. AbbVie is planning to establish operations in Right to Work Durham, North Carolina. The $1.4 billion investment is expected to create 734 new jobs for the community. Exciting! From Area Development Magazine: "Our investment in North Carolina represents a significant milestone for AbbVie as our largest capital investment to date and an important expansion of our manufacturing footprint into a new region of the United States. [...] By establishing this campus, we are strengthening our ability to support future medical breakthroughs while also creating new jobs and a long-term partnership with Durham and the State of North Carolina." [...] "This decision further cements North Carolina's position at the forefront of the global life sciences industry. [...] As our pharmaceutical sector grows, we remain fully committed to cultivating the highly skilled workforce, infrastructure, and ecosystem needed to deliver lifesaving medicines to patients around the world for companies like AbbVie." [...] "We are thrilled to welcome this significant investment, which serves as a powerful testament to Durham's growing reputation as a premier global hub for innovation and talent. [...] Beyond the economic impact, this partnership highlights the company's deep-rooted commitment to our community through sustainable growth and meaningful local engagement. Their decision to call Durham home reinforces our shared vision of a thriving, inclusive economy where corporate success and community prosperity go hand in hand." [...] "With continuous reinvestment in its training infrastructure, North Carolina remains eager to expand upon its strengths in biomanufacturing. [...] We are thrilled that AbbVie has selected Durham County and look forward to partnering to support the success of their North Carolina team." [...] "We're incredibly grateful that AbbVie chose Durham, bringing more than 700 high-quality jobs with six-figure average salaries. This is what real economic mobility looks like - creating pathways into the life sciences industry for more of our residents. [...] This win reflects what makes Durham special - strong partnership with the County, the Chamber, and coordinated execution across every City department, and we're proud to welcome AbbVie as a long-term community partner committed to our future." AREA DEVELOPMENT MAGAZINE

AllSci
Apr 13th, 2026
Haisco Pharma hands novel pain compound portfolio to AbbVie for USD 745m.

Haisco Pharma hands novel pain compound portfolio to AbbVie for USD 745m. April 13, 2026 A portfolio of novel pain compounds developed by Haisco Pharmaceutical Group (SZSE: 002653) has been licensed exclusively to AbbVie (NYSE: ABBV) under an agreement announced April 10, 2026. The deal grants AbbVie rights to develop, manufacture, and commercialize the compounds globally, excluding mainland China, Hong Kong, and Macau. The program covers multiple compounds at stages ranging from preclinical to Phase I in China, all targeting pain-related indications. Under the terms, Haisco receives a USD 30 million upfront payment and is eligible for up to USD 715 million in aggregate development, regulatory, and commercial milestones, bringing the total potential deal value to USD 745 million. Haisco is also eligible for tiered royalties on future net sales. Specific milestone triggers and royalty rates were not disclosed. Deal context. The compounds involved are described by Haisco as novel medicines for pain, but the press release does not identify specific molecule names, biological targets, or mechanisms of action. Haisco is known to be pursuing fast-follower NaV1.8 programs - targeting a voltage-gated sodium channel expressed in peripheral sensory neurons that plays a key role in pain signal transmission - following the approval of Vertex Pharmaceuticals' suzetrigine (Journavx) in January 2025. The Chinese firm has secured patents describing VX-548-derived scaffolds incorporating bioisosteric substitutions to modify the core structure. AbbVie has identified neuroscience as a core therapeutic focus alongside its established positions in immunology and oncology. However, the company has had limited recent deal activity specifically in pain, suggesting the Haisco transaction may represent an effort to expand its position in this segment within a broader neuroscience strategy. Other deals of note in the neuroscience space include the USD 8.7 billion acquisition of Cerevel Therapeutics in 2023, focused on later-stage CNS assets for schizophrenia, Parkinson's, and epilepsy. The deal also represents the latest collaboration between AbbVie with China-based partners. In January 2026, AbbVie struck a deal worth in excess of USD 5 billion with Remegen for a PD-1/VEGF bispecific antibody, while two separate partnerships were signed in 2025, with Zelgen Biopharmaceuticals for T-cell engagers, and Simcere Pharma for a trispecific antibody. For Haisco, the deal represents an extension of an international out-licensing strategy the company has pursued since 2015. Other notable partners include US based biotech AirNexis, which signed a deal worth in excess of USD 1 billion in January 2026 for PDE/4 respiratory asset of Haisco, HSK39004 The Chengdu-based company has R&D operations in Shanghai and Silicon Valley and has previously pursued international expansion through out-licensing, co-development, and acquisitions. Previous multinational partners include US biotech AirNexis and Italy's Chiesi Farmaceutici SpA. Your email address will not be published. Required fields are marked *

AInvest
Apr 13th, 2026
Haisco pharmaceuticals enters exclusive licensing agreement with AbbVie for pain medicines development.

Haisco pharmaceuticals enters exclusive licensing agreement with AbbVie for pain medicines development. Monday, Apr 13, 2026 2:26 am ET 1min read Haisco Pharmaceutical Group has entered into an exclusive licensing agreement with AbbVie to develop novel medicines for pain treatment globally, excluding mainland China, Hong Kong, and Macau. The program includes multiple compounds at various development stages. Haisco will receive a $30 million upfront payment and up to $715 million in milestone payments, plus royalties on future net sales. The collaboration is expected to generate sustainable value and long-term returns. Haisco Pharmaceutical Group has entered into an exclusive licensing agreement with AbbVie to develop and commercialize two Nav1.8 inhibitors for pain treatment outside of mainland China, Hong Kong, and Macau. The compounds, HSK55718 and HSK51155, are intended for the development of non-opioid analgesics and are at different stages of clinical development. HSK55718 is in Phase I clinical trials in China as an intravenous therapy, while HSK51155 is in the preclinical stage as an oral formulation according to the announcement. Under the terms of the agreement, Haisco will receive a $30 million upfront payment and is eligible for up to $715 million in milestone payments, in addition to royalties on future net sales. AbbVie will also cover certain research and development costs through the proof-of-concept phase. The deal is expected to support Haisco's global expansion and enhance its long-term profitability. The collaboration aligns with Haisco's strategy to advance its innovative drug portfolio and strengthen its international commercialization efforts. Ask Aime: What are the potential impacts of Haisco's licensing deal with AbbVie on its stock performance? Aime insights. What's the performance trend of major Indian companies listed on US stock exchanges? Between Microsoft and Google, which is better for long-term holding? How to evaluate a company's competitive advantage? How does R&D spending compare among semiconductor leaders over years?

WN.com
Apr 12th, 2026
AbbVie showcases late-breaking phase 2 data for mirvetuximab soravtansine-gynx (ELAHERE(R) in platinum-sensitive ovarian cancer (PSOC) at SGO 2026.

AbbVie showcases late-breaking phase 2 data for mirvetuximab soravtansine-gynx (ELAHERE(R) in platinum-sensitive ovarian cancer (PSOC) at SGO 2026.